Raymond James & Associates’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-100,984
| Closed | -$571K | – | 3885 |
|
|
2023
Q4 | $571K | Buy |
100,984
+9,604
| +11% | +$54.3K | ﹤0.01% | 2860 |
|
|
2023
Q3 | $170K | Buy |
91,380
+7,146
| +8% | +$13.3K | ﹤0.01% | 3477 |
|
|
2023
Q2 | $232K | Buy |
84,234
+21,132
| +33% | +$58.1K | ﹤0.01% | 3371 |
|
|
2023
Q1 | $198K | Buy |
63,102
+545
| +0.9% | +$1.71K | ﹤0.01% | 3466 |
|
|
2022
Q4 | $369K | Sell |
62,557
-875
| -1% | -$5.16K | ﹤0.01% | 3072 |
|
|
2022
Q3 | $556K | Buy |
63,432
+34,390
| +118% | +$301K | ﹤0.01% | 2781 |
|
|
2022
Q2 | $219K | Buy |
+29,042
| New | +$219K | ﹤0.01% | 3420 |
|